An overview of sipuleucel-T: Autologous cellular immunotherapy for prostate cancer

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 4, 2012, Pages 520-527

  Wesley, Johnna D ^a   Whitmore, James ^a   Trager, James ^a   Sheikh, Nadeem ^a  

^a Dendreon   (United States)

Author keywords

Active cellular therapy; Autologous cellular therapy; Immunotherapy; Prostate cancer; Sipuleucel T

Indexed keywords

ABIRATERONE; ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA INTERFERON; BCG VACCINE; CABAZITAXEL; CYTOKINE; DOCETAXEL; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; PA 2024; RECOMBINANT PROTEIN; SIPULEUCEL T; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; IMMUNOLOGIC FACTOR; TISSUE EXTRACT;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL CULTURE; CELLULAR IMMUNITY; CEREBROVASCULAR ACCIDENT; CHILL; DRUG APPROVAL; DRUG MANUFACTURE; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HUMORAL IMMUNITY; HYPERHIDROSIS; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFUSION; METASTASIS; MYALGIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; REVIEW; DRUG TOXICITY; IMMUNOTHERAPY; MALE; METHODOLOGY; PROSTATE TUMOR; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

CANCER VACCINES; DRUG TOXICITY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TISSUE EXTRACTS; TREATMENT OUTCOME; UNITED STATES;

EID: 84860757857     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.18769     Document Type: Review

References (52)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-36; PMID:21685461; http://dx.doi.org/10.3322/caac. 20121.
2. Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, et al. The immune system - is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol) 2008; 20:101-12; PMID:18037277; http://dx.doi.org/10.1016/j.clon.2007.10.011.
3. Sumner WC, Foraker AG. Spontaneous regression of human melanoma: clinical and experimental studies. Cancer 1960; 13:79-81; PMID:13835693; http://dx.doi.org/10.1002/1097-0142(196001/02)13:1〈79:: AIDCNCR2820130115〉3.0.CO;2-4.
4. Cole WH. Relationship of causative factors in spontaneous regression of cancer to immunologic factors possibly effective in cancer. J Surg Oncol 1976; 8:391-411; PMID:792571; http://dx.doi.org/10.1002/jso.2930080506.
5. Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm 2011; 26:1-64; PMID:21355777; http://dx.doi.org/10.1089/cbr.2010.0902.
6. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 2009; 9:704-16; PMID:19859065; http://dx.doi.org/10.1038/nri2635.
7. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355.
8. Schmitt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Hum Gene Ther 2009; 20:1240-8; PMID:19702439; http://dx.doi.org/10. 1089/hum.2009.146.
9. Berger C, Turtle CJ, Jensen MC, Riddell SR. Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 2009; 21:224-32; PMID:19304470; http://dx.doi.org/10.1016/j.coi.2009.02.010.
10. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157:220-33; PMID:19459844; http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x.
11. Riddell SR. Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med 2004; 200:1533-7; PMID:15611285; http://dx.doi.org/10.1084/ jem.20042004.
12. Riddell SR. Engineering antitumor immunity by T-cell adoptive immunotherapy. Hematology Am Soc Hematol Educ Program 2007; 250-6; PMID:18024637; http://dx.doi.org/10.1182/asheducation-2007.1.250.
13. Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J 2010; 16:304-10; PMID:20693840; http://dx.doi.org/10.1097/PPO.0b013e3181eb33d7.
14. Palena C, Abrams SI, Schlom J, Hodge JW. Cancer vaccines: preclinical studies and novel strategies. Adv Cancer Res 2006; 95:115-45; PMID:16860657; http://dx.doi.org/10.1016/S0065-230X(06)95004-0.
15. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA- and messenger RNA-based anticancer vaccination. Immunol Lett 2008; 115:33-42; PMID:18006079; http://dx.doi.org/10.1016/j.imlet.2007.09.012.
16. Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 2011; 18:305-17; PMID:21436867; http://dx.doi.org/10.1038/cgt.2011.7.
17. Loisel-Meyer S, Foley R, Medin JA. Immuno-gene threapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci 2008; 1:3202-14; http://dx.doi.org/10.2741/2921.
18. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-9; PMID:19536890; http://dx.doi.org/10.1002/cncr. 24429.
19. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
20. Graddis TJ, McMahan CJ, Tamman J, Page KJ, Trager JB. Prostatic acid phosphatase expression in human tissues. Int J Clin Exp Pathol 2011; 4:295-306; PMID:21487525.
21. Laus R, Yang DM, Ruegg CL, Shapero MH, Slagle PH, Small EJ, et al. Dendritic cell immunotherapy of prostate cancer: Preclinical models and early clinical experience. Cancer Research Therapy and Control 2001; 11:1-10.
22. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. Garland Science 2005.
23. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137:245-54; PMID:3086451.
24. Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother 2008; 57:1381-90; PMID:18297282; http://dx.doi.org/10.1007/s00262-008-0474-9.
25. FDA/CBER. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products 2011 January.
26. Sheikh NA, Dela Rosa C, Frohlich MW, Urdal DL, Provost NM. Sipuleucel-T treatment results in sequential ex vivo activation of APCs and T cells during the culture step - evidence for in vivo immunological priming [abstract]. AACR. Washington DC 2010.
27. Wesley JD, Chadwick E, Kuan LY, Dela Rosa C, Frohlich M, Urdal D, et al. Characterization of antigen specific T cell activation and cytokine expression induced by sipuleucel-T. J Immunother 2010; 33:912-3.
28. Sheikh NA, Wesley JD, Chadwick E, Perdue N, Dela Rosa C, Frohlich MW, et al. Characterization of antigen specifric T-cell activation and cytokine expression induced by sipuleucel-T. J Clin Oncol 2011; 29.
29. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6:2175-82; PMID:10873066.
30. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903; PMID:11099318.
31. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006; 107:67-74; PMID:16736512; http://dx.doi.org/10.1002/cncr.21956.
32. Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005; 4:55-60; PMID:15992463.
33. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-94; PMID:16809734; http://dx.doi.org/10.1200/JCO.2005.04.5252.
34. Butterfield LH, Disis ML, Khleif SN, Balwit JM, Marincola FM. Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med 2010; 8:130; PMID:21138581; http://dx.doi.org/10.1186/1479-5876-8-130.
35. Stewart FP, Dela Rosa C, Sheikh NA, McNeel DG, Frohlich MW, Urdal DL, et al. Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. [abstract 4552]. J Clin Oncol 2010; 28.
36. Sheikh NA, Dela Rosa C, Kuan LY, Stewart FP, Frohlich MW, Urdal DL, et al. Sipuleucel-T generates robust and persistent cellular and humoral immune responses - results from the IMPACT trial [abstract]. AACR. Washington DC 2010.
37. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011; 17:4558-67; PMID:21558406; http://dx.doi.org/10.1158/1078-0432.CCR-10-3223.
38. Augustin H, Freibauer C, Bayer L, Lunglmayr G, Tschurlovich F, Kuber W, et al. Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression. Prostate Cancer Prostatic Dis 2006; 9:279-83; PMID:16702984; http://dx.doi.org/10.1038/sj.pcan. 4500883.
39. Akyol F, Ozyigit G, Selek U, Karabulut E. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol 2005; 48:40-5; PMID:15967250; http://dx.doi.org/10.1016/j.eururo.2005.04.007.
40. Bates AT, Pickles T, Paltiel C. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62:148-53; PMID:15850915; http://dx.doi.org/10. 1016/j.ijrobp.2004.09.048.
41. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al.; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-59; PMID:18309951; http://dx.doi.org/10.1200/JCO.2007.12.4487.
42. Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007; 13:1488-92; PMID:17332293; http://dx.doi.org/10.1158/1078-0432.CCR-06- 1885.
43. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-105; PMID:20100959; http://dx.doi.org/10.1200/JCO.2009.25.0597.
44. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011; 17:907-17; PMID:21106727; http://dx.doi.org/10.1158/1078-0432. CCR-10-1762.
45. Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned and areas for further research. Clin Cancer Res 2011; 17:3884-91; PMID:21680544; http://dx.doi.org/10.1158/1078-0432.CCR-10-2656.
46. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010; 15:969-75; PMID:20798195; http://dx.doi.org/10. 1634/theoncologist.2010-0129.
47. Tuma RS. Immunotherapies in clinical trials: do they demand different evaluation tools? J Natl Cancer Inst 2011; 103:780-1; PMID:21551417; http://dx.doi.org/10.1093/jnci/djr184.
48. Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005; 11:2416-26; PMID:15788693; http://dx.doi.org/ 10.1158/1078-0432.CCR-04-1380.
49. Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. J Clin Oncol 2011; 29.
50. Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, et al. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol 2011; 186:877-81; PMID:21788048; http://dx.doi.org/10.1016/j. juro.2011.04.070.
51. Flanigan R, Price T, Whitmore J, Holman J. Safety of leukapheresis in prostate cancer patients receiving sipuleucel-T. J Urol 2011; 185:261; http://dx.doi.org/10.1016/j.juro.2011.02.1548.
52. Sims RB. Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 2011; In press; PMID:22122856; http://dx.doi.org/10.1016/j.vaccine.2011.11.058.